Skip to main content

FDA Drug Recalls

Every FDA drug enforcement recall Public Health Trace has on record, republished from openFDA's official drug enforcement database. See Health Alerts for current, active recalls alongside outbreaks and advisories.

Drug recall information is sourced from the FDA's structured openFDA Enforcement Reports. Newly announced recalls may appear on FDA.gov before they become available in the structured dataset. See Methodology for how Public Health Trace imports and refreshes this data.

Filters
Recall details
Location
Date range
Clear filters

Showing 7,901–7,920 of 17,964 drug recalls

Drug Recall Terminated Historical recordClass II

Revonto (dantrolene sodium for injection), 20 mg/vial, For treatment of malignant hyperthermia, For Intravenous Use Only, Rx Only, Made in Italy, Dist. by: US WorldMeds, LLC, Louisville, KY 40241, NDC: 27505-003-67

by US Worldmeds LLC

Reason
Presence of Precipitate: Appearance is Out of Specification for the reconstituted solution during 24-month stability time point analysis.
Recall initiated
April 25, 2019
Reported by FDA
May 8, 2019
Distribution
Nationwide in the USA

View recall →

Drug Recall Terminated Historical recordClass II

BEVACIZUMAB 1.25 mg/0.05 mL 31G MJ syringe Intravitreal Injection. This biologic product was repackaged by AmEx Pharmacy 1515 Elizabeth St. Suite J Melbourne, FL 32901 Lot:190212AB BUD:5/13/2019, Repackaged on 2/12/2019

by Pacifico National, Inc. dba AmEx Pharmacy

Reason
Defective Delivery System: difficult to express
Recall initiated
April 19, 2019
Reported by FDA
May 8, 2019
Distribution
Nationwide in the US

View recall →

Drug Recall Terminated Historical recordClass II

Losartan Potassium/HCTZ, 100 mg/12.5 mg Tablet, 90-Count bottle, Manufactured by Torrent Pharmaceuticals, Distributed by RemedyRepack, Inc. Indiana, PA, 15701-3570, NDC 70518-1560-00.

by RemedyRePack Inc.

Reason
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 0.96 parts per million.
Recall initiated
April 22, 2019
Reported by FDA
May 8, 2019
Distribution
Product was distributed to Florida.

View recall →

Drug Recall Ongoing Historical recordClass II

Losartan Potassium and Hydrochlorothiazide Tablets, USP, 100mg/25mg, a) 30-count (NDC: 13668-118-30) b) 90-count (NDC: 13668-118-90), c) 1000-count (NDC: 13668-118-10), per bottle, Rx only, Manufactured by: Torrent Pharmaceuticals LTD, Indrad-382 721, Dist. Mehsana India

by Torrent Pharma Inc.

Reason
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.
Recall initiated
April 18, 2019
Reported by FDA
May 8, 2019
Distribution
Nationwide USA and Puerto Rico

View recall →

Drug Recall Ongoing Historical recordClass II

Losartan Potassium and Hydrochlorothiazide Tablets, USP, 100mg/12.5mg, a) 90-count (NDC: 13668-117-90), b) 1000-count (NDC: 13668-117-10), per bottle, Rx only, Manufactured by: Torrent Pharmaceuticals LTD, Indrad-382 721, Dist. Mehsana India

by Torrent Pharma Inc.

Reason
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.
Recall initiated
April 18, 2019
Reported by FDA
May 8, 2019
Distribution
Nationwide USA and Puerto Rico

View recall →

Drug Recall Ongoing Historical recordClass II

Losartan Potassium and Hydrochlorothiazide Tablets, USP, 50mg/12.5mg, a) 30-count (NDC: 13668-116-30), b) 90-count (NDC: 13668-116-90), c) 1000-count (NDC: 13668-116-10), per bottle, Rx only, Manufactured by: Torrent Pharmaceuticals LTD, Indrad-382 721, Dist. Mehsana India

by Torrent Pharma Inc.

Reason
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.
Recall initiated
April 18, 2019
Reported by FDA
May 8, 2019
Distribution
Nationwide USA and Puerto Rico

View recall →

Drug Recall Ongoing Historical recordClass II

Losartan Potassium Tablets, USP, 100 mg, a) 90-count (NDC: 13668-115-90), b)1000-count (NDC: 13668-115-10) per bottle, Rx only, Manufactured by: Torrent Pharmaceuticals LTD, Indrad-382 721, Dist. Mehsana India

by Torrent Pharma Inc.

Reason
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.
Recall initiated
April 18, 2019
Reported by FDA
May 8, 2019
Distribution
Nationwide USA and Puerto Rico

View recall →

Drug Recall Ongoing Historical recordClass II

Losartan Potassium Tablets, USP, 50 mg, a) 90-count (NDC: 13668-409-90), b)1000-count (NDC: 13668-409-10) per bottle, Rx only, Manufactured by: Torrent Pharmaceuticals LTD, Indrad-382 721, Dist. Mehsana India

by Torrent Pharma Inc.

Reason
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.
Recall initiated
April 18, 2019
Reported by FDA
May 8, 2019
Distribution
Nationwide USA and Puerto Rico

View recall →

Drug Recall Ongoing Historical recordClass II

Losartan Potassium Tablets, USP, 25 mg, a) 90-count (NDC: 13668-113-90), b)1000-count (NDC: 13668-113-10) per bottle, Rx only, Manufactured by: Torrent Pharmaceuticals LTD, Indrad-382 721, Dist. Mehsana India

by Torrent Pharma Inc.

Reason
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.
Recall initiated
April 18, 2019
Reported by FDA
May 8, 2019
Distribution
Nationwide USA and Puerto Rico

View recall →

Drug Recall Ongoing Historical recordClass II

Losartan Potassium Tablets, USP, 50 mg, 30 tablet bottles, Rx Only, Distributed by: The Kroger Co, Cincinnati, OH 45202, Manufactured for: Torrent Pharma Inc., 150 Allen Road, Suite 102, Basking Ridge, NJ 07920, Packaged by: Legacy Pharmaceutical Packaging LLC, Earth City, MO 63045 NDC 68645-494-54

by Legacy Pharmaceutical Packaging LLC

Reason
CGMP Deviations: Detection of trace amounts of N-Methylnitrosobutyric acid (NMBA) impurity found in the Active Pharmaceutical Ingredient (API)
Recall initiated
April 24, 2019
Reported by FDA
May 8, 2019
Distribution
TN, AZ

View recall →

Drug Recall Terminated Historical recordClass II

TriMix MEDIUM (Papaverine HCL 21 mg/mL Phentolamine Mesylate 0.7 mg/mL Alprostadil 7 mcg/mL), 2 mL multidose MDV Inj. Compounded. Customceutical Compounding 4611 E. Shea Blvd. Bldg 3 180, Phoenix, AZ 85028 Ph. 480 516 0272

by Customceutical Compounding

Reason
Lack of assurance of sterility for injectables and solutions intended to be sterile.
Recall initiated
April 8, 2019
Reported by FDA
May 8, 2019
Distribution
U.S.A. Nationwide

View recall →

Drug Recall Terminated Historical recordClass II

Trimix HIGH (Papaverine HCl 30 mg/mL Phentolamine Mesylate 2 mg/mL Alprostadil 20 mcg/mL), 2 mL multidose vial MDV Inj. Compounded. Customceutical Compounding 4611 E. Shea Blvd. Bldg 3 180, Phoenix, AZ 85028 Ph. 480 516 0272

by Customceutical Compounding

Reason
Lack of assurance of sterility for injectables and solutions intended to be sterile.
Recall initiated
April 8, 2019
Reported by FDA
May 8, 2019
Distribution
U.S.A. Nationwide

View recall →

Drug Recall Terminated Historical recordClass II

Test PROCYP (TESTOSTERONE CYPIONATE 200MG/ML TESTOSTERONE PROPIONATE 20MG/ML), 5 ML MULTIDOSE VIAL INJ COMPOUNDED. Customceutical Compounding 4611 E. Shea Blvd. Bldg 3 180, Phoenix, AZ 85028 Ph. 480 516 0272

by Customceutical Compounding

Reason
Lack of assurance of sterility for injectables and solutions intended to be sterile.
Recall initiated
April 8, 2019
Reported by FDA
May 8, 2019
Distribution
U.S.A. Nationwide

View recall →

Drug Recall Terminated Historical recordClass II

Test D (TESTOSTERONE CYPIONATE 200MG/ML VITAMIN D3 5,000IU/ML), 5 ML MULTIDOSE VIAL COMPOUNDED. Customceutical Compounding 4611 E. Shea Blvd. Bldg 3 180, Phoenix, AZ 85028 Ph. 480 516 0272

by Customceutical Compounding

Reason
Lack of assurance of sterility for injectables and solutions intended to be sterile.
Recall initiated
April 8, 2019
Reported by FDA
May 8, 2019
Distribution
U.S.A. Nationwide

View recall →

Drug Recall Terminated Historical recordClass II

Test D (TESTOSTERONE CYPIONATE 200MG/ML VITAMIN D3 5,000IU/ML), 5 ML MULTIDOSE VIAL COMPOUNDED. Customceutical Compounding 4611 E. Shea Blvd. Bldg 3 180, Phoenix, AZ 85028 Ph. 480 516 0272

by Customceutical Compounding

Reason
Lack of assurance of sterility for injectables and solutions intended to be sterile.
Recall initiated
April 8, 2019
Reported by FDA
May 8, 2019
Distribution
U.S.A. Nationwide

View recall →

Drug Recall Terminated Historical recordClass II

Lipoplex (METHIONINE 25 MG/ML INOSITOL 50 MG/ML CHOLINE CHLORIDE 50 MG/ML HYDROXOCOBALAMIN 500 MC/ML DEXPANTHENOL 50 MG/ML PYRIDOXINE HCL 50 MG/ML), 10 ML MULTIDOSE VIAL INJ COMPOUNDED. Customceutical Compounding 4611 E. Shea Blvd. Bldg 3 180, Phoenix, AZ 85028 Ph. 480 516 0272

by Customceutical Compounding

Reason
Lack of assurance of sterility for injectables and solutions intended to be sterile.
Recall initiated
April 8, 2019
Reported by FDA
May 8, 2019
Distribution
U.S.A. Nationwide

View recall →

Drug Recall Terminated Historical recordClass II

HCG (CHORIONIC GONADOTROPIN 1000 IU/ML PEP 25 mg/mL) inj 5 mL multidose vial compounded. Customceutical Compounding 4611 E. Shea Blvd. Bldg 3 180, Phoenix, AZ 85028 Ph. 480 516 0272

by Customceutical Compounding

Reason
Lack of assurance of sterility for injectables and solutions intended to be sterile.
Recall initiated
April 8, 2019
Reported by FDA
May 8, 2019
Distribution
U.S.A. Nationwide

View recall →

Drug Recall Terminated Historical recordClass II

Glutathione 200mg/mL inj. a) 10 ML and b) 12 ML MULTIDOSE VIAL MDV Compounded. Customceutical Compounding 4611 E. Shea Blvd. Bldg 3 180, Phoenix, AZ 85028 Ph. 480 516 0272

by Customceutical Compounding

Reason
Lack of assurance of sterility for injectables and solutions intended to be sterile.
Recall initiated
April 8, 2019
Reported by FDA
May 8, 2019
Distribution
U.S.A. Nationwide

View recall →

Drug Recall Terminated Historical recordClass II

BPlex (METHYLCOBALAMIN 1000 MCG/ML PYRIDOXAL 5 PHOSPHATE 20MG/ML DEXPANTHENOL 250MG/ML), 10 ML MULTIDOSE VIAL MDV INJ COMPOUNDED. Customceutical Compounding 4611 E. Shea Blvd. Bldg 3 180, Phoenix, AZ 85028 Ph. 480 516 0272

by Customceutical Compounding

Reason
Lack of assurance of sterility for injectables and solutions intended to be sterile.
Recall initiated
April 8, 2019
Reported by FDA
May 8, 2019
Distribution
U.S.A. Nationwide

View recall →

Drug Recall Terminated Historical recordClass II

BPlex (METHYLCOBALAMIN 1000 MCG/ML PYRIDOXAL 5 PHOSPHATE 20MG/ML DEXPANTHENOL 250MG/ML), 10 ML MULTIDOSE VIAL MDV INJ COMPOUNDED. Customceutical Compounding 4611 E. Shea Blvd. Bldg 3 180, Phoenix, AZ 85028 Ph. 480 516 0272

by Customceutical Compounding

Reason
Lack of assurance of sterility for injectables and solutions intended to be sterile.
Recall initiated
April 8, 2019
Reported by FDA
May 8, 2019
Distribution
U.S.A. Nationwide

View recall →

Data last updated:

This information is republished from FDA's Recall Enterprise System through openFDA. Public Health Trace does not verify or supplement it, is not affiliated with the FDA, and does not provide medical advice -- always follow the guidance of your pharmacist, physician, or the recalling company for any medication you take. Read the full medical disclaimer.